跳至主要内容
临床试验/NCT01869062
NCT01869062已完成不适用

Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography

MicroPort CRM1 个研究点 分布在 1 个国家目标入组 348 人开始时间: 2013年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
348
试验地点
1
主要终点
CRT-responders rate increase based on LVESV decrease at M6 / baseline

研究概览

简要总结

The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT parameters by SonR technology is able to increase the rate of CRT-D responders, based on significant LV reverse remodeling, as compared to Standard of Care settings.

This study will also evaluate the effectiveness of CRT-D SonR system as compared to Standard of care (SoC) programming methods in providing appropriate LV filling, as expected from the Ritter method.

详细描述

This study will evaluate the effectiveness of CRT-D SonR system as compared to SoC programming methods to:

  • Increase the rate of patients responding to CRT
  • Provide appropriate hemodynamic cardiac effect, as expected from the Ritter method.

The identification of CRT responders, as defined by echocardiography, generally refers to a significant reduction of the LV End-Systolic Diameter (LVESD) and/or LVESV during Follow-Up (FUp).

Patients will be considered as responders to CRT if their LVESV decreased by > 15% after 6 months of CRT therapy as compared to baseline. The percentage of CRT responders will be compared between the two study arms.

SoC is defined as the standard CRT system programming/optimization method currently used by physicians in study centers and any method may be used in the study if considered as routine practice in the study center.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines ;
  • •In Sinus Rhythm;
  • •Have reviewed, signed and dated an informed consent

排除标准

  • •Previous implant with a pacemaker, an Implantable Cardioverter-Defibrillator or a CRT device (except upgrade from single chamber ICD with a fully functional defibrillation lead not under recall or surveillance);
  • •Persistent atrial arrhythmias (or cardioversion for Atrial Fibrillation) within the past month;
  • •Ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
  • •Incessant ventricular tachyarrhythmia;
  • •Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past 4 weeks;
  • •Correctable valvular disease that is the primary cause of heart failure;
  • •Mechanical heart valve or indication for valve repair or replacement;
  • •Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months);
  • •Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
  • •Already included in another clinical study that could confound the results of this study;
  • •Life expectancy less than 1 year;
  • •Inability to understand the purpose of the study;
  • •Unavailability for scheduled follow-up or refusal to cooperate;
  • •Sensitivity to 1 mg Dexamethasone Sodium Phosphate (DSP);
  • •Age of less than 18 years;
  • •Pregnancy;
  • •Drug addiction or abuse;
  • •Under guardianship

研究组 & 干预措施

SonR CRT Optimization 'On'

Other

CRT-D device with the SonR optimization algorithm programmed being 'on'.

干预措施: SonR CRT Optimization 'On' (Device)

SonR CRT Optimization 'Off'

Other

CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).

干预措施: SonR CRT Optimization 'Off' (Device)

结局指标

主要结局

CRT-responders rate increase based on LVESV decrease at M6 / baseline

时间窗: 6 months

For the purpose of this study, CRT-responders are defined as patients experiencing a decrease in LVESV of 15% or more at M6 Fup as most clinical trials used. The main objective of the SONR-ECHO trial is to show a minimum increase of CRT-responders rate of 15% (up to 72% or more) in the SonR study group as compared to SoC arm.

次要结局

  • A-wave truncation assessment at M6(6 months)

研究者

发起方
MicroPort CRM
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验